Table 1.
Demographic and clinical characteristics.
Fig 1.
a. Index: first pregabalin claim. b. Neuropathic pain (NeP): diabetic peripheral neuropathy, spinal cord injury, or post-herpetic neuralgia within 12 months prior to or 1 month following the index. c. Non-NeP indications: epilepsy, fibromyalgia, amyotrophic lateral sclerosis, or multiple sclerosis. d. New pregabalin users: no pregabalin use within 12 months prior to the index.
Table 2.
Inclusion and exclusion criteria with coding algorithms.
Table 3.
Patterns of dose titration.
Table 4.
Logistic regression for factors associated with adherence (MPR≥0.8).
Fig 2.
Kaplan-Meier analysis of months to pregabalin discontinuation or switch.
Table 5.
Cox proportional hazards model for factors associated with treatment discontinuation or switch.